Repository logo
Log in(current)
Repository logoMIT Open ScholarshipDSpace@MIT
  1. Home
  2. MIT Open Access Articles
  3. MIT Open Access Articles
  4. Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors

Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors

Thumbnail Image
Download
Name

Adalsteinsson_et_al-2017-Nature_Communications.pdf

Size

1.4 MB

Format

Adobe PDF

Checksum (MD5)

d13a363ddcdee8065c897db9646cb087

Download all files submitted through automated deposit
sword-2017-12-11.original.zip (975.5 KB)
Author(s)
Ha, Gavin
•
Freeman, Samuel S.
•
Choudhury, Atish D.
•
Stover, Daniel G.
•
Parsons, Heather A.
•
Gydush, Gregory
•
Reed, Sarah C.
•
Rotem, Denisse
•
Rhoades, Justin
•
Livitz, Dimitri
more
Date Issued
November 2017
Journal
Nature Communications
Publisher
Nature Publishing Group
Citation
Adalsteinsson, Viktor A. et al. “Scalable Whole-Exome Sequencing of Cell-Free DNA Reveals High Concordance with Metastatic Tumors.” Nature Communications 8, 1 (November 2017): 1324 © 2017 The Author(s)
Version
Final published version
Abstract
Whole-exome sequencing of cell-free DNA (cfDNA) could enable comprehensive profiling of tumors from blood but the genome-wide concordance between cfDNA and tumor biopsies is uncertain. Here we report ichorCNA, software that quantifies tumor content in cfDNA from 0.1× coverage whole-genome sequencing data without prior knowledge of tumor mutations. We apply ichorCNA to 1439 blood samples from 520 patients with metastatic prostate or breast cancers. In the earliest tested sample for each patient, 34% of patients have ≥10% tumor-derived cfDNA, sufficient for standard coverage whole-exome sequencing. Using whole-exome sequencing, we validate the concordance of clonal somatic mutations (88%), copy number alterations (80%), mutational signatures, and neoantigens between cfDNA and matched tumor biopsies from 41 patients with ≥10% cfDNA tumor content. In summary, we provide methods to identify patients eligible for comprehensive cfDNA profiling, revealing its applicability to many patients, and demonstrate high concordance of cfDNA and metastatic tumor whole-exome sequencing.
MIT Department
Massachusetts Institute of Technology. Department of Chemical Engineering
Koch Institute for Integrative Cancer Research at MIT
Terms of Use
Creative Commons Attribution 4.0 International
https://creativecommons.org/licenses/by/4.0/
Persistent DSpace Link
http://hdl.handle.net/1721.1/112694
DOI of Published Version
https://doi.org/10.1038/s41467-017-00965-y
Repository logo
PrivacyPermissionsAccessibilityContact us
Repository logo
Notify us about copyright concerns.